Revenue ₹2,470 Cr (+16.7% YoY)
0 met · 0 close · 1 missed across 1 tracked promises
View all executive profiles for Emcure Pharmaceuticals LtdEmcure delivered a strong Q4 FY26 with revenue of ₹2,470 crore (+16.7% YoY) and EBITDA margin expansion of 130 bps to...
0% promises delivered
Based on 1 tracked promises across 3 quarters
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Quarterly Earnings Timeline
Financial verification status, call summary, sentiment, and management-delivery signals by quarter.
Q4 FY26
15 May 2026
Revenue ₹2,470 Cr (+16.7% YoY)
Emcure delivered a strong Q4 FY26 with revenue of ₹2,470 crore (+16.7% YoY) and EBITDA margin expansion of 130 bps to 19.7%, driven by robust international growth (+25...
bullish
high
Scorecard starts after historical backfill
Read full analysis →
Q3 FY26
03 Feb 2026
Revenue ₹2,363 Cr (+20.4% YoY)
Emcure delivered a strong Q3 FY26 with revenue of ₹2,363 crore (+20.4% YoY) and EBITDA margin expansion of 110 bps to 19.5%, driven by operating leverage and productiv...
bullish
high
1 missed
Read full analysis →
Q1 FY26
06 Aug 2025
Revenue ₹2,100 Cr (+15.7% YoY)
Emcure delivered a strong Q1 FY26 with revenue of ₹2,100 crore (+15.7% YoY), EBITDA of ₹404 crore (+20.1% YoY), and PAT of ₹215 crore (+41% YoY).
bullish
high
Scorecard starts after historical backfill
Read full analysis →